The European Commission, the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) published on Monday 19 December, as part of the ‘ACT EU’ joint initiative to accelerate clinical trials in the European Union, recommendations to facilitate the conduct of decentralised clinical trials in the European Union and the European Economic Area.
The new approach should allow clinical trial participants to travel less frequently to centralised clinical trial sites. This...